Get the Stockscreener App
4.10
1.68%
-0.07
Corvus Pharmaceuticals Inc stock is traded at $4.10, with a volume of 604.71K.
It is down -1.68% in the last 24 hours and up +6.22% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$4.17
Open:
$4.1
24h Volume:
604.71K
Relative Volume:
0.60
Market Cap:
$279.49M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-7.3214
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
-12.95%
1M Performance:
+6.22%
6M Performance:
-23.51%
1Y Performance:
+37.12%
1-Day Range:
$3.96
$4.12
1-Week Range:
$3.96
$4.76
52-Week Range:
$2.54
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
4.10 | 321.57M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
What recovery options are there for Corvus Pharmaceuticals Inc.Free AI Powered High Return Stock Calls - Newser
Real time pattern detection on Corvus Pharmaceuticals Inc. stockFree Real Profit Trade Plan Suggestions - Newser
Smart tools for monitoring Corvus Pharmaceuticals Inc.’s price actionFree Alpha Driven Watchlist With Alerts - Newser
What makes Corvus Pharmaceuticals Inc. stock price move sharplyBreakout Stocks Watchlist That Work - jammulinksnews.com
Institutional scanner results for Corvus Pharmaceuticals Inc.Free Daily Stock Market Swing Alerts - Newser
Custom watchlist performance reports with Corvus Pharmaceuticals Inc.Safe Investment Ideas with Growth Upside - Newser
New Product Launches: Will They Boost Corvus Pharmaceuticals Inc. Stock in 2025Free Stock Portfolio Allocation Guidance - Newser
Applying chart zones and confluence areas to Corvus Pharmaceuticals Inc.Predictable Entry Strategy With Technical Backing - Newser
Can swing trading help recover from Corvus Pharmaceuticals Inc. lossesSafe Investment Ideas with Growth Upside - Newser
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025 - The Manila Times
Clinical-Stage Biotech Corvus Pharmaceuticals Sets Q2 2025 Earnings Release: Key Updates Coming August 7 - Stock Titan
What are the latest earnings results for Corvus Pharmaceuticals Inc.Beginner Investor Ideas For Smart Trading - jammulinksnews.com
Price action breakdown for Corvus Pharmaceuticals Inc.AI Trade Signal Forecast with Chart Logic - Newser
Published on: 2025-07-30 23:35:48 - Newser
How Corvus Pharmaceuticals Inc. stock performs during market volatilityFree Reliable Alerts for Daily Stock Movers - Newser
Why Corvus Pharmaceuticals Inc. stock attracts strong analyst attentionReal Time Growth Signal with Smart Setup - Newser
Is Corvus Pharmaceuticals Inc. Stock a Smart Buy in 2025 Investment Analysis InsideWeekly Stock Watch With Growth Focus Expanded - metal.it
Quant Tools Rank Corvus Pharmaceuticals Inc. as High Risk High Reward - metal.it
How volatile is Corvus Pharmaceuticals Inc. stock compared to the marketInvest smarter with advanced market data - jammulinksnews.com
What are analysts’ price targets for Corvus Pharmaceuticals Inc. in the next 12 monthsLightning-fast capital gains - jammulinksnews.com
Screener Results Flag Corvus Pharmaceuticals Inc. as OversoldHigh Accuracy Alerts for ROI Traders Detected - beatles.ru
Is Corvus Pharmaceuticals Inc. stock overvalued or undervaluedPre Market Forecasts For 2025 - jammulinksnews.com
Is it the right time to buy Corvus Pharmaceuticals Inc. stockBreakthrough stock performance - jammulinksnews.com
Is Corvus Pharmaceuticals Inc. a growth stock or a value stockBuild a diversified portfolio for steady growth - jammulinksnews.com
Corvus Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayReal Time Stock Signal - Newser
How does Corvus Pharmaceuticals Inc. generate profit in a changing economySuperior return velocity - jammulinksnews.com
Corvus Pharmaceuticals Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingFree Low-Risk Investment Plans - Newser
Is Corvus Pharmaceuticals Inc. stock a growth or value playRapid-fire capital growth - jammulinksnews.com
What drives Corvus Pharmaceuticals Inc. stock priceSuperior profit margins - PrintWeekIndia
Corvus Pharma Bets On Immunotherapy And Analyst Optimism - Finimize
What analysts say about Corvus Pharmaceuticals Inc. stockPhenomenal capital gains - jammulinksnews.com
Is Corvus Pharmaceuticals Inc. a good long term investmentFree AI-Backed Trading Signals - jammulinksnews.com
Corvus Pharmaceuticals Inc. Stock Analysis and ForecastOverwhelming profit margins - jammulinksnews.com
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):